Intuitive Surgical Weathers Reuse Controversy as Goldman Sachs Stands Behind Da Vinci Growth Case
Intuitive Surgical faced questions about the unauthorized reuse of single-use surgical instruments in some markets, a practice that raises safety and regulatory concerns. Goldman Sachs responded by reaffirming its view on the company's underlying fundamentals, citing the durable adoption trajectory of robotic-assisted surgery.
The Reuse Controversy
Intuitive Surgical builds and sells the Da Vinci surgical robotics platform, which is used in minimally invasive procedures including prostatectomies, hysterectomies, and cardiac surgeries. A recurring challenge for the company is the unauthorized reuse of single-use surgical instruments by some hospital systems, particularly in cost-sensitive markets outside the US. Instruments designed for a single procedure are occasionally resterilized and reused, which can compromise performance, raise infection risk, and reduce the revenue Intuitive captures per procedure.
The reuse issue is not new, but periodic reports and regulatory inquiries around it can weigh on investor sentiment, as each reused instrument represents lost consumable revenue that the company would otherwise earn. The recurring instrument revenue stream is a key part of the investment thesis: once a Da Vinci system is placed in a hospital, the ongoing consumables business provides predictable, high-margin revenue.
Goldman Sachs on the Fundamentals
Goldman Sachs chose to use the renewed reuse discussion as an opportunity to reaffirm the core investment case on ISRG. The bank highlighted that the long-run adoption of robotic-assisted surgery remains structurally underpenetrated, with procedure volumes growing across general surgery, thoracic, and colorectal categories. Intuitive Surgical's competitive position with the Da Vinci platform, and its newer Ion robotic bronchoscopy system, gives it durable pricing power and customer lock-in.
The company has also invested in next-generation platforms. Its Da Vinci 5 system, launched in recent quarters, includes force feedback capability and improved instrument performance that may reduce the marginal appeal of instrument reuse by delivering more perceptible benefits from using fresh instruments.
Margin and Installed Base Dynamics
Intuitive Surgical's installed base of Da Vinci systems exceeded 9,000 systems globally as of its most recent disclosures, a figure that reflects years of capital sales and creates a massive recurring consumables and service revenue opportunity. As the installed base grows, the ratio of high-margin instrument-and-accessory revenue to lower-margin capital equipment revenue improves, which is a favourable mix shift.
Sources
Frequently asked questions
What is the instrument reuse issue for Intuitive Surgical?
Some hospitals, particularly in cost-sensitive international markets, resterilize and reuse Intuitive Surgical's single-use instruments rather than purchasing new ones for each procedure. This reduces Intuitive's consumable revenue per procedure and raises regulatory and patient-safety concerns.
Why is Goldman Sachs backing Intuitive Surgical despite the reuse controversy?
Goldman Sachs views the reuse issue as a structural challenge that Intuitive is aware of and managing, rather than a fundamental threat to the business. The analysts point to durable growth in robotic-assisted surgery adoption, expanding procedure categories, and the company's strong installed base of Da Vinci systems as reasons the core investment thesis remains intact.
Informational only, not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.
One story is a data point. The pattern is the edge.
Reading one story at a time, you miss how the news adds up. Track ISRG free and TradeTidings rolls every future headline into one clear positive, neutral or negative read, and alerts you the moment it turns.